Counseling Before Treatment and Interpreting a New Corneal Finding in a Responding Patient

The moderator and the panelists then discuss how to prepare the patient for the first cycles. The moderator then presents a 62-year-old patient about 4 months into a belantamab mafodotin regimen and close to a very good partial response, with new corneal findings and reduced visual acuity in 1 eye, blurred vision, and trouble reading and driving at night. The other panelist reads the report through visual acuity and corneal findings. The panelists then discuss the clinical scenario, their interpretations, and their recommendations based on the provided information.